TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01323192
Drug: JNS001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JNS001 (18 mg, 36 mg, 54 mg or 72 mg per day) orally once daily for 8 weeks.
Study: NCT01323192
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo orally once daily for 8 weeks.
Study: NCT00754884
Drug: intranasal saline solution plus glycerol
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily intranasal (one shot) saline solution plus glycerol for a period of 14 days
Study: NCT01820481
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bid, PO, 12weeks
Study: NCT00364884
Drug: ketoaminoacid
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01248325
Drug: Luffa Operculate Nasal Solution 5mg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment will start on the first visit in which subjects will be instructed to instill in the nasal passages, 3 drops of the product by morning and 3 drops of the product at night.
Study: NCT01430390
Drug: Cyclophosphamide-based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide-based chemotherapy regimen will be the preferred conditioning chemotherapy prior to CAR T cell infusion for patients with CD19+ malignancy in cohort 1. Recommended chemotherapy regimen consists of single agent Cyclophosphamide at a dose of 3000 mg/m2/dose IV over 1 hour or 1500mg/m2/dose x 2 doses given daily over 1 hour given for 2 days (patients may received reduced dose of cyclophosphamide based on the clinical status of the patient at discretion of the treating physician and with written approval by the MSKCC PI of this study). Alternative cyclophosphamide or non-cyclophosphamide-based regimens based on the clinical status of the patient, disease burden, and likely-hood of response may be used at the discretion of the treating physician with written approval by MSKCC PI of the study. Conditioning chemotherapy will not be given prior to infusions # 2 and #3.
Study: NCT02946801
Drug: Essential oils
Normalized name: essential oils
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04058587
Drug: Simmitinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: The core trial period includes 4-weeks Screening stage (28d), 7-days single administration stage, 4-weeks multiple administration stage (28d), 3-days blood collection stage of PK after multiple administration.~The starting dose was set at 1mg/d on toxicology data. Dosing will continue uninterrupted for 28 days in multiple administration stage.~The dose-limiting toxicity (DLT) period assessment will be from the first administration of Simmitinib tablet to the end of the first cycle (35 days).
Study: NCT02906566
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of Retinol
Study: NCT00241332
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02796755
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants randomized to this arm will take a placebo, that matches the appearance of 100 mg tablets of riluzole, daily for 8 weeks.
Study: NCT02400879
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administering remifentanil infusion 0.7-0.8 mcg/kg/min for anesthesia maintenance
Study: NCT01510574
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x placebo tablets resembling misoprostol taken orally
Study: NCT00626080
Drug: Insulin NPH
Normalized name: insulin NPH human isophane
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 IU/ml, QD, dose individually adjusted, to be used for a period of 12 weeks; in combination with insulin aspart TID
Study: NCT02665910
Drug: SHR0302
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets (1 mg, 5 mg, 10 mg)
Study: NCT02665910
Drug: SHR0302 placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets (1 mg, 5 mg, 10 mg) (matching corresponding study medication)
Study: NCT02400879
Drug: sevoflurane and sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: administering sevoflurane and sufentanil for anesthesia maintenance
Study: NCT03235050
Drug: MEDI0382 mid dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution Route of administration: subcutaneous
Study: NCT03235050
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution Route of administration: subcutaneous
Study: NCT04219982
Drug: DPI-386 Placebo Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPI-386 Placebo Nasal Gel
Study: NCT04219982
Drug: Transderm Scop®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transderm Scop®
Study: NCT00089492
Drug: Optimized Background ARVs
Approvals — FDA: no, EMA: no, PMDA: no
Description: As prescribed
Study: NCT01706484
Drug: BNO 1016
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparison of different dosages of drug and placebo
Study: NCT03137498
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac 30mg (1ml) intravenous push injection x 1dose
Study: NCT03603106
Drug: P03277
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part I: P03277 was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.~Part II: P03277 was administered intravenously with a flow rate of 2 mL/s.
Study: NCT03603106
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part I: Placebo was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.~Part II: Placebo was administered intravenously with a flow rate of 2 mL/s.
Study: NCT02286635
Drug: Deflazacort and Clarithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects. It is an inactive pro-drug which is metabolized completely and rapidly to the active drug 21 desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone. Clarithromycin is a semi-synthetic macrolide antibiotic. Clarithromycin is active in vitro against a variety of aerobic and anaerobic gram-positive and gram-negative bacteria as well as most mycobacterium avium complex (MAC) bacteria. Additionally, the 14-OH clarithromycin metabolite also has clinically significant antimicrobial activity. Clarithromycin is indicated for the treatment of mild to moderate infections such as pharyngitis/tonsillitis.
Study: NCT00775931
Drug: Campath-1H
Approvals — FDA: no, EMA: no, PMDA: no
Description: Campath-1H will be administered 0.3 mg/kg subcutaneously per day for three days starting on Day -21 through Day -19.
Study: NCT00775931
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (50 mg/kg/dose) will be given IV on day -4, -3, -2 and -1 over 2 hours. The total dose to be given over 4 days is 200 mg/kg for cord blood grafts-receiving patients only.
Study: NCT01988831
Drug: Placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: We use placebo pills alike propranolol commercial pills to ensure blindness of the subjects during the study.
Study: NCT00519818
Drug: Chronocort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronocort 30 mg once daily nigh time dose for 28 +/- 3 days duration
Study: NCT00590447
Drug: sequential R-CHOP
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375 mg/m2 rituximab, IV on days 1, 8, 15, 22, 50, 72, 94 and 116. Cyclophosphamid 750 mg/m2, adriamycine 50 mg/m2 and vincristine 1.4mg/m2, IV and prednisone 50mg/m2, PO every 3 weeks at days 50, 72, 94 and 116.~In case of disease progression during the first 4 administration of rituximab antibody or the 4 weeks interval between antibody and R-CHOP administration the patients directly enter R-CHOP chemotherapy.
Study: NCT01854684
Drug: Photodynamic Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undergo intraoperative PDT
Study: NCT00885755
Drug: Standard taxane therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: As prescribed
Study: NCT00885755
Drug: capecitabine [Xeloda]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg/m2 po bid on days 1-14 of each 3-week cycle (only in patients who have progressed)
Study: NCT01603654
Drug: low-volume PEG -ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: THe product is used as colon cleanser before colonoscopy. It is supplied as a powder for oral use, to be reconstituted with 2 L of water and drunk as a solution. It consists of 100.0 g macrogol 3350 plus electrolytes (7.5 g sodium sulphate, 2.7 g sodium chloride, 1.0 g potassium chloride) and 4.7 g ascorbic acid.
Study: NCT00328172
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching BI 1356
Study: NCT01343888
Drug: PegIFN/RBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: PegIFN/RBV for 48 weeks
Study: NCT01343888
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00751478
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00503490
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID
Study: NCT00335829
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00335829
Drug: embolization therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01838993
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00854360
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFA Vehicle Aerosol
Study: NCT03307720
Drug: Gonadotropin Releasing Hormone Agonists (GNRH-A)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of a gonadotropin releasing hormone agonist (GnRH-a) (0,2 ml) subcutaneously, 36 hours before ovum pick-up in IVF treatments.
Study: NCT04466540
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine placebo
Study: NCT01747941
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT01064752
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg po bid for 8 weeks
Study: NCT00034814
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme-inducing placebo TID
Study: NCT00034814
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-enzyme-inducing placebo TID
Study: NCT03985735
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: For maintenance of propofol anesthesia, total intravenous anesthesia was administered by using propofol (Fresenius Kabi, Austria GmbH) at a plasma target concentration (Marsh pharmacokinetic model software) of 2.5-4 μg/ml. Remifentanil (0.2-0.5 μg/kg/min) was given to all patients during the operation. Additional cisatracurium （0.05 mg/kg）and fentanyl (30-50 μg at the end of surgery) were used as needed, in accordance with the clinical requirements.
Study: NCT00506142
Drug: Marqibo® (vincristine sulfate liposomes injection)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every 2 weeks.~Cohort 2 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every week.
Study: NCT00644839
Drug: CP-945,598
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of CP-945,598 alone in period 1
Study: NCT00644839
Drug: CP-945,598
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adminstration of CP-945,598 with omeprazole in period 2
Study: NCT01366339
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03475134
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
Study: NCT00859833
Drug: Adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Myocardial perfusion reserve measured with quantitative MRI during adenosine infusion (0.14 mg/kg/min x 6 minutes).
Study: NCT04352114
Drug: LY3461767 - SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT04352114
Drug: LY3461767 - IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV.
Study: NCT04352114
Drug: Placebo - SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT03184415
Drug: DWC20155
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet
Study: NCT03184415
Drug: DWC20156
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet
Study: NCT03184415
Drug: placebo of DWC20155
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet
Study: NCT03184415
Drug: placebo of DWC20156
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet
Study: NCT02712788
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06231212
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen group was given capsules containing 200 mg of ibuprofen
Study: NCT00000212
Drug: Desipramine
Normalized name: Desipramine
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02864810
Drug: [18F]GP1
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18F\]GP1 PET/CT imaging for detecting thromboembolism
Study: NCT01486628
Drug: ND0612
Approvals — FDA: no, EMA: no, PMDA: no
Description: levodopa and carbidopa solution for subcutaneous administration
Study: NCT01486628
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline solution for SC continuous administration
Study: NCT01276106
Drug: AC-201, 25mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, 25mg BID
Study: NCT01276106
Drug: AC-201, 50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, 50mg BID
Study: NCT01276106
Drug: AC-201, 75mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, 75mg BID
Study: NCT01276106
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo BID
Study: NCT00003573
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00649103
Drug: Accupril® Tablets 40 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg, single dose fasting
Study: NCT00510276
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice a day, by mouth for 12 weeks
Study: NCT03063658
Drug: Ibuprofen 800 mg
Normalized name: ibuprofen 800 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The first dose of 800 mg intravenous ibuprofen will be administered preoperatively and the remaining three doses will be given each six hours in the early postoperative period.
Study: NCT00005830
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02441894
Drug: PEG-G-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Study: NCT02441894
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT02525679
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00685061
Drug: Campath-1H
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction
Study: NCT04314622
Drug: Supaglutide
Normalized name: Supaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT04314622
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT02009579
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5) + paclitaxel (175 mg/m2) and placebo 200 mg BID followed by placebo maintenance until progression or for a total maximum duration of 120 weeks.
Study: NCT05204121
Drug: Elpida
Approvals — FDA: no, EMA: no, PMDA: no
Description: elsulfavirine, capsules
Study: NCT03218969
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT01591629
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04302116
Drug: Combination therapy with vigabatrin and prednisolone
Normalized name: prednisolone, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose prednisolone (40 - 60 mg/day) for 1 month combined with vigabatrin treatment (50-150 mg/kg/day) twice daily for 4 months
Study: NCT01879007
Drug: Factive® Tab / Factive IV
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03622047
Drug: No analgesia labor
Approvals — FDA: no, EMA: no, PMDA: no
Description: No analgesia labor control group
Study: NCT00245141
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01062867
Drug: ORG25435
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intended doses: 0.25, 0.5, 1.0, 2.0, 3.0, 4.0, 5.0 and 6.0 mg/kg by intravenous infusion over 1 min Up to 25mg/kg by infusion over 30min
Study: NCT01712347
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: The protocol does not specify the chemotherapy regimen to be used, the choice of chemotherapy will be at the discretion of treating physician.
Study: NCT02935764
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400mg/m2 iv gtt,d1
Study: NCT00640003
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo drug
Study: NCT00163098
Drug: UK-369,003
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00336713
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration (capsules)
Study: NCT02647671
Drug: Aquamin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 days of Aquamin
Study: NCT02647671
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 days of placebo
Study: NCT01871441
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03703505
Drug: [13C6]AG-348
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV microdose of approximately 100 micrograms (mcg), single dose.
Study: NCT01991379
Drug: MEK162
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients should take the study drug with a glass of water. MEK162 can be taken with or without food.
Study: NCT00527943
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablets; matching placebo for vorapaxar; loading and maintenance dosing; once daily for at least 1 year
Study: NCT04476992
Drug: Nitric Oxide-Sessions
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric Oxide will be delivered at 200 ppm in 2 daily sessions (morning, evening; 9-12 hours apart) for 14 days. Each session will last 30 minutes, for a total of 60 minutes/day for each patient. A tank of NO gas will be connected to the inspiratory limb of the circuit, and the flow will be adjusted to deliver a target concentration of 200 ppm NO. Commercially available tanks will be used to provide the gas. The desired mixture of air, oxygen (O2), and NO will be titrated with the respective flowmeter to reach a concentration of 200 ppm at the inspiratory limb with the desired Fraction of inspired oxygen (FiO2).
Study: NCT04476992
Drug: Nitric Oxide-Continuous and Sessions
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric Oxide will be delivered at 200 ppm in 2 daily sessions (morning, evening; 9-12 hours apart) for 14 days. Each session will last 30 minutes, for a total of 60 minutes/day for each patient. A tank of NO gas will be connected to the inspiratory limb of the circuit, and the flow will be adjusted to deliver a target concentration of 200 ppm NO. Commercially available tanks will be used to provide the gas. The desired mixture of air, oxygen (O2), and NO will be titrated with the respective flowmeter to reach a concentration of 200 ppm at the inspiratory limb with the desired Fraction of inspired oxygen (FiO2).~The subjects assigned to the group NO High Concentration + Continuous Low Concentration will receive in adjunction a continuous dose of NO at 20 ppm.
Study: NCT01533545
Drug: Mepivacaine with epinephrine
Normalized name: epinephrine / mepivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided infraclavicular brachial plexus block with mepivacaine 400 mg (10 mg/mL) mixed with epinephrine 200 μg (5 μg/mL)
Study: NCT01451645
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily placebo dosing for 16 weeks
Study: NCT00854646
Drug: ON 01910.Na
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drug is a sterile, concentrated 75mg/mL solution in polyethylene glycol 400, in labeled, sealed glass vials. The Concentrate must be diluted with aqueous infusion solutions (0.9% NaCl, USP and Water for Injection, USP according to instructions) immediately prior to intravenous administration.
Study: NCT00003490
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00906386
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, 1 mg twice daily, 12 weeks
Study: NCT00217165
Drug: taurine
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: taurine 2mg BID po
Study: NCT01982812
Drug: Standard AED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active comparitor, Standard AED
Study: NCT01966549
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile, 5 percent dextrose will be used as the placebo in this study. Placebo will be administered by intravenous infusion on Weeks 0, 2, 4, 8 and 12.
Study: NCT01342094
Drug: Placebo ophthalmic solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01578161
Drug: 0.9% Normal Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo,Normal saline 10ml ivs. for 10min.